Skip to main content
Premium Trial:

Request an Annual Quote

Bruker Daltonics Posts Big Revenues, Higher Profits for Q3

NEW YORK, Nov. 5-Bruker Daltonics yesterday posted strong income and powerful revenue growth for the third quarter of 2002

 

The company reported a net income of $1.7 million or 3 cents per diluted share for the three months ended September 30, 2002. The figure is up sharply from the third quarter of 2001, when Bruker reported net income of $925,000 or 2 cents per diluted share.

 

Net revenues for the period were $29.7 million, up 25 percent from the $23.8 million that the company posted in the third quarter of 2001. Revenues exceeded consensus estimates.

 

Bruker's R&D spending was $5.1 million for the quarter, up from $4.8 million in Q3 of 2001.

 

The company held cash and short-term investments of $49.6 million as of September 30, 2002.

 

For further details, see the company statement.

The Scan

Dropped Charges

The US Justice Department has dropped visa fraud charges against five Chinese researchers, according to the Wall Street Journal.

More Kids

The Associated Press says Moderna is expanding its SARS-CoV-2 vaccine study to included additional children and may include even younger children.

PNAS Papers on Rat Clues to Human Migration, Thyroid Cancer, PolyG-DS

In PNAS this week: ancient rat genome analysis gives hints to human migrations, WDR77 gene mutations in thyroid cancer, and more.

Purnell Choppin Dies

Purnell Choppin, a virologist who led the Howard Hughes Medical Institute, has died at 91, according to the Washington Post.